Intuitive Surgical (NASDAQ:ISRG) PT Raised to $565.00 at Robert W. Baird

Intuitive Surgical (NASDAQ:ISRG) had its target price upped by equities researchers at Robert W. Baird from $503.00 to $565.00 in a research note issued to investors on Thursday. Robert W. Baird’s price target suggests a potential upside of 19.06% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Citigroup boosted their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Truist Financial boosted their price target on Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a report on Monday. Barclays lifted their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Morgan Stanley increased their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Finally, Raymond James lifted their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $484.15.

Intuitive Surgical Stock Performance

NASDAQ:ISRG traded down $2.04 during mid-day trading on Thursday, reaching $474.55. 651,718 shares of the company’s stock were exchanged, compared to its average volume of 1,459,238. The firm has a market capitalization of $168.32 billion, a PE ratio of 85.71, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a one year low of $254.85 and a one year high of $496.48. The business’s fifty day simple moving average is $482.49 and its two-hundred day simple moving average is $436.65.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the firm earned $1.18 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, equities research analysts forecast that Intuitive Surgical will post 5.22 EPS for the current year.

Insider Activity

In other news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,655,048.26. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock worth $25,528,753 in the last quarter. 0.90% of the stock is owned by corporate insiders.

Institutional Trading of Intuitive Surgical

Institutional investors and hedge funds have recently modified their holdings of the stock. Creekmur Asset Management LLC lifted its position in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. Ridgewood Investments LLC purchased a new stake in Intuitive Surgical in the 2nd quarter valued at about $26,000. Delos Wealth Advisors LLC lifted its position in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares in the last quarter. LRI Investments LLC purchased a new position in shares of Intuitive Surgical in the 1st quarter worth approximately $30,000. Finally, LGT Financial Advisors LLC grew its holdings in shares of Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 54 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.